InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,304.72
(
0.70%
)
US TECH 100
18,318.00
(
0.95%
)
Dow Jones
39,069.59
(
0.01%
)
Brent Oil
81.97
(
0.00%
)
Bitcoin
68,982.20
(
-0.41%
)
Post# of 97237
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

read_this_n0w

Send PM Follow Ignore
Followers 250
Posts 14020
Boards Moderated 3
Alias Born 07/07/2006

read_this_n0w

Re: $heff post# 92005

Wednesday, 12/16/2015 3:12:23 PM

Wednesday, December 16, 2015 3:12:23 PM

Post# of 97237
PTC Therapeutics has positive read through from EMA agenda, says Oppenheimer
After European drug regulator EMA published its draft agenda for a December 14-17 meeting, Oppenheimer says the agenda indicates that the agency will decide whether to adopt the company's Translama drug, rather than consider evidence about it or just discuss it. The firm thinks the agency could release a positive opinion about the drug sooner than expected. It keeps a $135 price target and Outperform rating on the shares

Feedback is allways appreciated, as are other (annotated) picks
Twitter: @RTNRTN To follow on ihub: Ihub mark

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up